We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
As with any medicine, the MHRA will keep the safety and effectiveness of fluticasone propionate under close review.
How to use a multiphase optimisation strategy (MOST) to evaluate your digital health product.
A call for evidence has been launched on the approval and marking of road vehicles placed on the market in Great Britain.
How to use a cost utility analysis to evaluate your digital health product.
Apply for a High Potential Individual (HPI) visa if you've been awarded a qualification by an eligible university in the last 5 years - eligibility, fees, documents, switch, bring your partner and children
Data on the real-world efficacy of the COVID-19 vaccines.
Preventing people in England from developing high blood pressure (hypertension), and detecting and managing it better in those who have it.
Guidance on choosing evaluation study types and methods.
How to use a cost effectiveness analysis to evaluate your digital health product.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).